Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewO-Phospho-L-serine
Discontinued Product
0238 has been discontinued.
View all Glutamate (Metabotropic) Group III Receptors products.
说明： Group III mGlu agonist
别名： L-SOP
化学名： L-Serine-O-phosphate
生物活性 for O-Phospho-L-serine
O-Phospho-L-serine is a group III metabotropic glutamate receptor agonist; analog of L-AP4 (Cat. No. 0103). Neuroprotective against excitotoxicity in cortical cell cultures. Inhibits proliferation and enhances neuronal differentiation in progenitor cells.
技术数据 for O-Phospho-L-serine
| 分子量 | 185.07 |
| 公式 | C3H8NO6P |
| 储存 | Store at RT |
| CAS Number | 407-41-0 |
| PubChem ID | 68841 |
| InChI Key | BZQFBWGGLXLEPQ-REOHCLBHSA-N |
| Smiles | [H][C@@](COP(O)(O)=O)(N)C(O)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for O-Phospho-L-serine
参考文献 for O-Phospho-L-serine
参考文献是支持产品生物活性的出版物。
Bruno et al (1996) Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures. Eur.J.Pharmacol. 310 61 PMID: 8880068
Eriksen and Thomsen (1995) [3H]-L-2-amino-4-phosphonobutyrate labels a metabotropic glutamate receptor, mGluR4a. Br.J.Pharmacol. 116 3279 PMID: 8719808
Thoreson and Ulphani (1995) Pharmacology of selective and non-selective metabotropic glutamate receptor agonists at L-AP4 receptors in ON bipolar cells. Brain Res. 676 93 PMID: 7796182
Saxe et al (2007) A phenotypic small-molecule screen identifies an orphan ligand-receptor pair that regulates neural stem cell differentiation. Chem.Biol. 14 1019 PMID: 17884634
Yang et al (2016) A chemical biology route to site-specific authentic protein modifications. Science 354 623 PMID: 27708052
Park et al (2011) Expanding the genetic code of Escherichia coli with phosphoserine. Science 333 1151 PMID: 21868676
按标靶查看相关产品
关键词: O-Phospho-L-serine, O-Phospho-L-serine supplier, Group, III, mGlur, agonists, Receptors, mGlu4, mGlu6, mGlu7, mGlu8, mGluR4, mGluR6, mGluR7, mGluR8, Glutamate, Metabotropic, stem, cells, o-phosphoserine, sep, L-SOP, (Metabotropic), Neural, Stem, Cells, 0238, Tocris Bioscience
2 篇 O-Phospho-L-serine 的引用文献
引用文献是使用了 Tocris 产品的出版物。 O-Phospho-L-serine 的部分引用包括：
Jiang et al (2006) Activation of group III metabotropic glutamate receptors attenuates rotenone toxicity on DArgic neurons through a microtubule-dependent mechanism. J Neurosci 26 4318 PMID: 16624952
Mathiesen et al (2003) Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol 138 1026 PMID: 12684257
O-Phospho-L-serine 的评论
目前没有该产品的评论。 Be the first to review O-Phospho-L-serine and earn rewards!
Have you used O-Phospho-L-serine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.